PURPOSE: Synopsis of the introductory paragraph of the DEGRO consensus S2e-guideline recommendations for the radiotherapy of benign disorders, including physical principles, radiobiological mechanisms, and radiogenic risk. MATERIALS AND METHODS: This work is based on the S2e-guideline recommendations published November 14, 2013. The basic principles of radiation physics and treatment delivery, evaluation of putative underlying radiobiological mechanisms, and the assessment of genetic and cancer risk following low-dose irradiation will be presented. RESULTS: Radiation therapy of benign diseases is performed according to similar physical principles as those governing treatment of malignant diseases in radiation oncology, using the same techniques and workflows. These methods comprise usage of orthovoltage X-ray units, gamma irradiation facilities, linear accelerators (LINACs), and brachytherapy. Experimental in vitro and in vivo models recently confirmed the clinically observed anti-inflammatory effect of low-dose X-irradiation, and implicated a multitude of radiobiological mechanisms. These include modulation of different immunological pathways, as well as the activities of endothelial cells, mono- and polymorphonuclear leukocytes, and macrophages. The use of effective dose for radiogenic risk assessment and the corresponding tumor incidence rate of 5.5%/Sv are currently controversially discussed. Some authors argue that the risk of radiation-induced cancers should be estimated on the basis of epidemiological data. However, such data are rarely available at present and associated with high variability. CONCLUSION: Current radiobiological studies clearly demonstrate a therapeutic effectiveness of radiation therapy used to treat benign diseases and implicate various molecular mechanisms. Radiogenic risks should be taken into account when applying radiation treatment for benign diseases.
PURPOSE: Synopsis of the introductory paragraph of the DEGRO consensus S2e-guideline recommendations for the radiotherapy of benign disorders, including physical principles, radiobiological mechanisms, and radiogenic risk. MATERIALS AND METHODS: This work is based on the S2e-guideline recommendations published November 14, 2013. The basic principles of radiation physics and treatment delivery, evaluation of putative underlying radiobiological mechanisms, and the assessment of genetic and cancer risk following low-dose irradiation will be presented. RESULTS: Radiation therapy of benign diseases is performed according to similar physical principles as those governing treatment of malignant diseases in radiation oncology, using the same techniques and workflows. These methods comprise usage of orthovoltage X-ray units, gamma irradiation facilities, linear accelerators (LINACs), and brachytherapy. Experimental in vitro and in vivo models recently confirmed the clinically observed anti-inflammatory effect of low-dose X-irradiation, and implicated a multitude of radiobiological mechanisms. These include modulation of different immunological pathways, as well as the activities of endothelial cells, mono- and polymorphonuclear leukocytes, and macrophages. The use of effective dose for radiogenic risk assessment and the corresponding tumor incidence rate of 5.5%/Sv are currently controversially discussed. Some authors argue that the risk of radiation-induced cancers should be estimated on the basis of epidemiological data. However, such data are rarely available at present and associated with high variability. CONCLUSION: Current radiobiological studies clearly demonstrate a therapeutic effectiveness of radiation therapy used to treat benign diseases and implicate various molecular mechanisms. Radiogenic risks should be taken into account when applying radiation treatment for benign diseases.
Authors: Barbara Lödermann; Roland Wunderlich; Silke Frey; Christine Schorn; Sonja Stangl; Franz Rödel; Ludwig Keilholz; Rainer Fietkau; Udo S Gaipl; Benjamin Frey Journal: Int J Radiat Biol Date: 2012-05-22 Impact factor: 2.694
Authors: F Rödel; B Frey; U Gaipl; L Keilholz; C Fournier; K Manda; H Schöllnberger; G Hildebrandt; C Rödel Journal: Curr Med Chem Date: 2012 Impact factor: 4.530
Authors: Matthias G Hautmann; Ernst-Michael Jung; Lukas P Beyer; Christoph Süß; Felix Steger; Markus Weber; Fabian Pohl; Oliver Kölbl; Franz Josef Putz Journal: Strahlenther Onkol Date: 2018-10-30 Impact factor: 3.621
Authors: Oliver Micke; Eyup Ugrak; Stefan Bartmann; Irenaeus A Adamietz; Ulrich Schaefer; Rebecca Bueker; Klaus Kisters; M Heinrich Seegenschmiedt; Khashayar Fakhrian; Ralph Muecke Journal: Radiat Oncol Date: 2018-04-19 Impact factor: 3.481
Authors: Jan Kriz; Heinrich M Seegenschmiedt; Amelie Bartels; Oliver Micke; Ralph Muecke; Ulrich Schaefer; Uwe Haverkamp; Hans T Eich Journal: Adv Radiat Oncol Date: 2018-02-26
Authors: Alexander Rühle; Elisabeth Tkotsch; Rainer Mravlag; Erik Haehl; Simon K B Spohn; Constantinos Zamboglou; Peter E Huber; Jürgen Debus; Anca-Ligia Grosu; Tanja Sprave; Nils H Nicolay Journal: Strahlenther Onkol Date: 2021-08-03 Impact factor: 3.621